Wall Street brokerages expect MannKind Co. (NASDAQ:MNKD – Get Rating) to announce earnings per share (EPS) of ($0.10) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for MannKind’s earnings, with estimates ranging from ($0.13) to ($0.08). MannKind reported earnings of ($0.05) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The business is expected to report its next earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that MannKind will report full year earnings of ($0.35) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.26). For the next financial year, analysts forecast that the firm will post earnings of ($0.03) per share, with EPS estimates ranging from ($0.16) to $0.09. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover MannKind.
MannKind (NASDAQ:MNKD – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.05). The business had revenue of $12.52 million during the quarter, compared to analysts’ expectations of $16.99 million. During the same period in the prior year, the firm posted ($0.06) EPS.
Shares of MannKind stock opened at $3.13 on Thursday. The business has a 50-day moving average price of $3.45 and a two-hundred day moving average price of $4.01. MannKind has a 1-year low of $2.49 and a 1-year high of $5.53. The company has a market cap of $789.57 million, a P/E ratio of -9.78 and a beta of 1.98.
In other MannKind news, insider Alejandro Galindo purchased 36,900 shares of the company’s stock in a transaction that occurred on Monday, February 28th. The shares were acquired at an average price of $2.71 per share, with a total value of $99,999.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Anthony C. Hooper purchased 40,000 shares of the company’s stock in a transaction that occurred on Monday, February 28th. The stock was acquired at an average cost of $2.71 per share, for a total transaction of $108,400.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 79,945 shares of company stock valued at $218,052. 2.30% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of MNKD. Oakworth Capital Inc. bought a new position in shares of MannKind during the 1st quarter worth approximately $25,000. Macquarie Group Ltd. bought a new position in shares of MannKind during the 3rd quarter worth approximately $26,000. Russell Investments Group Ltd. bought a new position in shares of MannKind during the 4th quarter worth approximately $39,000. PYA Waltman Capital LLC bought a new position in shares of MannKind during the 4th quarter worth approximately $43,000. Finally, Paradigm Financial Partners LLC bought a new stake in shares of MannKind in the 4th quarter worth approximately $43,000. 43.41% of the stock is currently owned by hedge funds and other institutional investors.
About MannKind (Get Rating)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
- Get a free copy of the StockNews.com research report on MannKind (MNKD)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.